Alzheimer’s drug approval controversy

Both items concern politically salient, high‑profile accelerated drug reviews that risk producing public controversy over standards and trust; here the FDA’s priority vouchers for Compass Pathways, Usona and Transcend echo past disputes about fast approvals (e.g., Aduhelm) and raise similar concerns about evidentiary thresholds and regulatory signaling.

By arguing the A→T→N model is robust and acknowledging modest clinical effects of anti-amyloid drugs like Aduhelm, the piece underpins decisions about approving and reimbursing costly anti-amyloid therapies, shaping evidence thresholds and Medicare policy.

Article claims approved anti-amyloid antibodies cost tens of thousands annually yet offer imperceptible benefit and notable risks.